Selina Luger
Specializes in acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. Presented on a phase two study comparing giltaritinib versus midostaurin in newly diagnosed FLT3 mutated AML.
Best podcasts with Selina Luger
Ranked by the Snipd community
Mar 28, 2025 • 23min
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!
Selina Luger, an expert in leukemias, and Curtis Lachowiez, a hematological malignancies authority, discuss groundbreaking strategies for optimizing induction therapy in acute myeloid leukemia. They delve into the exciting results of combining venetoclax with traditional chemotherapy, showcasing enhanced remission rates. Additionally, Luger shares insights from trials comparing FLT3 inhibitors, while Lachowiez highlights the potential of menin inhibitors like Ziftomenib. The conversation also touches on the effectiveness of CPX-351 and future advancement directions in AML treatment.
May 28, 2021 • 10min
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
Experts discuss challenges in treating older patients with ALL, diagnostic testing for Ph-like ALL, and interventions to prevent relapse after stem cell transplantation.
